FindTrial
Sign In

Shanghai Clinical Cohort : Demonstrative Clinical Cohort Construction for Cervical Cancer

Shanghai Clinical Team — Cervical Cancer (Demonstration)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116207
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Observation group:None

Sponsors

Fudan University Affiliated Obstetrics and Gynecology Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: In 2025, 1600 patients with cervical cancer will be newly included, and the storage rate of biological samples will reach 60%; Among them, About 25% patients with lesions >= 4cm can ensure that enough samples of cervical cancer/adjacent tissues can be obtained for multi-group sequencing. Without affecting the pathological diagnosis; At the same time, it is necessary to consider the loss in the process of sampling, transportation and quality control in the early stage of sequencing. (about 35%), so it is planned to be included in the biological sample database of cervical cancer (matched cervical cancer and adjacent cancer) 1600*25%*(1-35%) is about 200 cases, and the subsequent proteomic sequencing is based on these 200 cases.

Exclusion criteria

Exclusion criteria: Non-cervical cancer patients

Design outcomes

Primary

MeasureTime frame
Sequencing of cervical tissue samples;—

Countries

CHINA

Contacts

Public ContactkeqinHua

Fudan University Affiliated Obstetrics and Gynecology Hospital

huakeqin@fdu.edu.cn+86 159 2151 5900

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026